This case-based course details the multi-step process of treatment decision-making for an older woman with early-stage, HER2-positive and hormone receptor-positive breast cancer. Life expectancy estimation, goals of treatment and calculation of treatment benefits and toxicities are explored in the context of shared clinician-patient decision making.
Upon participation in this activity, learners will be better able to:
Hyman B. Muss, MD, FASCO
University of North Carolina/Lineberger Comprehensive Cancer Center
Chapel Hill, NC
Disclosure of Relationships with Companies
Financial relationships reported by course faculty, planners, and reviewers (F = Faculty, P = Planner, R = Reviewer).
During all phases of planning and development, areas of conflict were managed through a peer-review process and/or through individual recusal when appropriate. All relationships are considered self-held and compensated unless otherwise noted (I= Immediate family member; Inst= My Institution).
Hyman B. Muss, MD (F): No relationships to disclose
Helen K. Chew, MD (P, R): Honoraria - Novartis
Tyler Paul Johnson, MD (P, R): Employment - HemOncReview.com; Other Relationship - Heme/Onc Questions
This activity was supported by ASCO eLearning. No funds or in-kind contributions from commercial entities were used for support.
Disclaimer / Unlabeled Usage Statement
The information presented is that of the contributing authors and does not necessarily represent the views of the American Society of Clinical Oncology. Specific therapies discussed may not be approved and / or specified for use as indicated. Therefore, before prescribing any medication, please review the complete prescribing information including indications, contraindications, warnings, precautions and adverse effects.
Your feedback will help guide us in the next phase of this program. Please take a few minutes (estimated 2 minutes) to answer the following 6 questions.